The role of Müller cell glucocorticoid signaling in diabetic retinopathy.
Diabetic retinopathy
Gene therapy
Glucocorticoid signaling
Müller cells
Journal
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
ISSN: 1435-702X
Titre abrégé: Graefes Arch Clin Exp Ophthalmol
Pays: Germany
ID NLM: 8205248
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
08
08
2019
accepted:
22
10
2019
revised:
14
10
2019
pubmed:
18
11
2019
medline:
2
12
2020
entrez:
18
11
2019
Statut:
ppublish
Résumé
Diabetic retinopathy (DR) is a sight-threatening complication associated with the highly prevalent diabetes disorder. Both the microvascular damage and neurodegeneration detected in the retina caused by chronic hyperglycemia have brought special attention to Müller cells, the major macroglia of the retina that are responsible for retinal homeostasis. Given the role of glucocorticoid signaling in anti-inflammatory responses and the almost exclusive expression of glucocorticoid receptors (GRs) in retinal Müller cells, administration of corticosteroid agonists as a potential treatment option has been widely studied. Although these approaches have been moderately efficacious in treating or de-escalating DR pathomechanisms, there are various side effects and gaps of knowledge with regard to introducing exogenous glucocorticoids to the diseased retina. In this paper, we provide a review of the literature concerning the available evidence for the role of Müller cell glucocorticoid signaling in DR and we discuss previously investigated approaches in modulating this system as possible treatment options. Furthermore, we propose a novel alternative to the available choices of treatment by using gene therapy as a tool to regulate the expression of GR in retinal Müller cells. Upregulating GR expression allows for induced glucocorticoid signaling with more enduring effects compared to injection of agonists. Hence, repetitive injections would no longer be required. Lastly, side effects of glucocorticoid therapy such as glucocorticoid resistance of GR following chronic exposure to excess ligands or agonists can be avoided.
Identifiants
pubmed: 31734719
doi: 10.1007/s00417-019-04521-w
pii: 10.1007/s00417-019-04521-w
doi:
Substances chimiques
Receptors, Glucocorticoid
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
221-230Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : GR 4403/2-1
Organisme : Deutsche Forschungsgemeinschaft
ID : HA6014/5-1
Organisme : University of British Columbia
ID : UBC-Germany Scholarship
Références
Cold Spring Harb Perspect Biol. 2016 May 02;8(5):
pubmed: 27141051
Curr Diab Rep. 2017 Aug 24;17(10):93
pubmed: 28836097
Mol Cell Neurosci. 2004 Aug;26(4):493-502
pubmed: 15276152
J Cell Physiol. 2017 May;232(5):1123-1134
pubmed: 27580405
Diabetes. 2006 Mar;55(3):633-9
pubmed: 16505225
Diabetes. 2009 Jul;58(7):1659-67
pubmed: 19401417
Proc Natl Acad Sci U S A. 1999 Oct 12;96(21):11776-81
pubmed: 10518526
JAMA. 2005 Mar 23;293(12):1509-13
pubmed: 15784876
J Neuroinflammation. 2019 Feb 18;16(1):43
pubmed: 30777091
J Cell Physiol. 2009 Jan;218(1):66-74
pubmed: 18767037
Mol Ther. 2018 Jan 3;26(1):256-268
pubmed: 29033008
Cell. 2015 May 21;161(5):1202-1214
pubmed: 26000488
Am J Physiol Regul Integr Comp Physiol. 2004 Oct;287(4):R735-41
pubmed: 15371279
Cell Mol Neurobiol. 2012 Feb 2;32(3):467-475
pubmed: 22297541
Retina. 2007 Sep;27(7):816-24
pubmed: 17891003
Exp Eye Res. 2008 Oct;87(4):385-93
pubmed: 18687327
Front Oncol. 2019 Apr 24;9:297
pubmed: 31069169
Diabetologia. 2018 Jan;61(1):29-38
pubmed: 28942458
J Neurosci. 2012 Nov 7;32(45):15715-27
pubmed: 23136411
Neurochem Int. 2001 Apr;38(5):385-90
pubmed: 11222918
Biochimie. 2003 Aug;85(8):747-52
pubmed: 14585541
Glia. 2013 May;61(5):651-78
pubmed: 23440929
Mol Vis. 2007 Jan 31;13:133-41
pubmed: 17293777
Dose Response. 2011;9(3):332-47
pubmed: 22013396
Exp Eye Res. 2011 Jan;92(1):87-93
pubmed: 21111734
Vision Res. 2017 Oct;139:93-100
pubmed: 28866025
Curr Diab Rep. 2011 Aug;11(4):244-52
pubmed: 21590515
Exp Eye Res. 2006 Sep;83(3):473-83
pubmed: 16750526
Endocr Rev. 2014 Aug;35(4):671-93
pubmed: 24937701
Clin Ophthalmol. 2015 Jul 16;9:1321-35
pubmed: 26213460
Int J Mol Med. 2007 Jan;19(1):75-9
pubmed: 17143550
Diabetes. 2008 Apr;57(4):995-1001
pubmed: 18223010
Eye Vis (Lond). 2015 Sep 30;2:17
pubmed: 26605370
Exp Clin Endocrinol Diabetes. 2014 Apr;122(4):201-7
pubmed: 24623503
Graefes Arch Clin Exp Ophthalmol. 2007 May;245(5):627-36
pubmed: 17219109
Glia. 2014 Jul;62(7):1110-24
pubmed: 24687761
Prog Retin Eye Res. 2003 Jul;22(4):545-62
pubmed: 12742394
Diabetes. 2005 Dec;54 Suppl 2:S40-5
pubmed: 16306339
Diabetes Obes Metab. 2015 Mar;17(3):219-30
pubmed: 25160598
EMBO J. 2001 Nov 1;20(21):6071-83
pubmed: 11689447
PLoS One. 2012;7(7):e41511
pubmed: 22911805
Exp Neurol. 2015 Nov;273:114-25
pubmed: 26272753
Cytokine Growth Factor Rev. 2016 Oct;31:1-15
pubmed: 27185365
Mol Endocrinol. 1995 Apr;9(4):401-12
pubmed: 7659084
PLoS One. 2011;6(10):e26498
pubmed: 22046295
Invest Ophthalmol Vis Sci. 2011 Nov 21;52(12):8944-50
pubmed: 22003113
Cell. 2019 Feb 21;176(5):1222-1237.e22
pubmed: 30712875
Diabetes Care. 2007 Jan;30(1):83-8
pubmed: 17192338
Curr Mol Med. 2014 Mar;14(3):376-84
pubmed: 24467200
Steroids. 2018 May;133:60-66
pubmed: 29129720
JCI Insight. 2017 Jul 20;2(14):null
pubmed: 28724805
Biochem Soc Trans. 2003 Dec;31(Pt 6):1343-8
pubmed: 14641060
Physiol Behav. 2017 Sep 1;178:166-171
pubmed: 28089708
Circ Res. 2010 Oct 29;107(9):1058-70
pubmed: 21030723
J Clin Invest. 1998 Aug 15;102(4):783-91
pubmed: 9710447
Diabetes. 1998 May;47(5):815-20
pubmed: 9588455
Development. 2014 Sep;141(17):3340-51
pubmed: 25085975
J Neuroimmunol. 2005 Apr;161(1-2):145-54
pubmed: 15748953
Graefes Arch Clin Exp Ophthalmol. 2006 Feb;244(2):226-31
pubmed: 16049703
Mol Metab. 2018 Mar;9:156-167
pubmed: 29373286
Diabetes Care. 2012 Mar;35(3):556-64
pubmed: 22301125
J Clin Invest. 2012 Nov;122(11):3849-51
pubmed: 23093785
Trends Neurosci. 1996 Aug;19(8):307-12
pubmed: 8843598
Glia. 2014 Sep;62(9):1476-85
pubmed: 24838936
J Diabetes Complications. 1998 Jan-Feb;12(1):24-7
pubmed: 9442811
Arch Ophthalmol. 2004 Dec;122(12):1801-7
pubmed: 15596583
Invest Ophthalmol Vis Sci. 2002 Sep;43(9):3109-16
pubmed: 12202536
J Steroid Biochem Mol Biol. 2002 Dec;83(1-5):37-48
pubmed: 12650700
Rev Endocr Metab Disord. 2008 Dec;9(4):315-27
pubmed: 18654858
Glycoconj J. 2016 Aug;33(4):513-25
pubmed: 27406712
Neuroreport. 2000 Nov 9;11(16):3533-7
pubmed: 11095513
N Engl J Med. 2008 May 22;358(21):2231-9
pubmed: 18441371
Blood. 2014 Jan 30;123(5):625-31
pubmed: 24300855
World J Diabetes. 2015 Feb 15;6(1):92-108
pubmed: 25685281
Open Ophthalmol J. 2013;7:4-10
pubmed: 23459241
Neurosci Lett. 2006 Mar 27;396(2):97-101
pubmed: 16330144
Mech Ageing Dev. 2010 Apr;131(4):276-86
pubmed: 20307566
Biochem J. 2005 Feb 15;386(Pt 1):e1-e3
pubmed: 15702493
Lancet. 2010 Jun 26;375(9733):2215-22
pubmed: 20609967
Pharmacol Ther. 2017 May;173:1-18
pubmed: 28132907
Dis Model Mech. 2012 Jul;5(4):444-56
pubmed: 22730475
Cell Biosci. 2014 May 14;4:27
pubmed: 24955234
J Cell Sci. 2003 Jun 15;116(Pt 12):2495-503
pubmed: 12734399
Signal Transduct Target Ther. 2017;2:
pubmed: 29158945
Mol Cell. 2012 Jul 13;47(1):38-49
pubmed: 22633955
Curr Neuropharmacol. 2016;14(8):831-839
pubmed: 27306035
Gene Ther. 2009 Jan;16(1):10-6
pubmed: 18633446
Rheum Dis Clin North Am. 2016 Feb;42(1):15-31, vii
pubmed: 26611548
Proc Natl Acad Sci U S A. 2012 Jul 17;109(29):11776-81
pubmed: 22753499
Physiol Rev. 2013 Jan;93(1):137-88
pubmed: 23303908